INSM Stock Recent News

BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share.

Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.

Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.

BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients with a rare lung disease.

Michelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.

Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The company said patients in the study with non-cystic fibrosis bronchiectasis who were dosed with brensocatib saw statistically significant reductions in the annualized rate of pulmonary exacerbations compared to placebo.

Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ratio but substantial long-term debt. Peak revenue estimates for brensocatib range from $1-5 billion, with a reasonable midpoint of $3 billion expected.

Insmed stock catapulted Tuesday after the biotech company experimental lung disease treatment succeeded in a final-phase study.

Insmed (NASDAQ: INSM ) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis. This saw brensocatib reach its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo.